ASCO 2025 | Improving patient selection for immunotherapies in the future using biomarkers & resistance patterns
In this video, Akiva Diamond, MD, Baylor College of Medicine, Houston, TX, briefly comments on the potential of improving patient selection for immunotherapies by using biomarkers and resistance patterns to guide treatment decisions. Dr Diamond highlights that more research is required in this area, as the currently published studies and reports do not provide consistent evidence for any specific biomarkers. This interview took place during the 2025 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
There’s been several reports and several studies and nothing’s been really consistent in every single report. We’re seeing that antigen loss is a mechanism of resistance, but that seems to be a little bit later and maybe about 30% of patients. So my thought is that if we could have deeper initial responses, we may prevent antigen escape from ever happening...
There’s been several reports and several studies and nothing’s been really consistent in every single report. We’re seeing that antigen loss is a mechanism of resistance, but that seems to be a little bit later and maybe about 30% of patients. So my thought is that if we could have deeper initial responses, we may prevent antigen escape from ever happening. But there, you know, as I mentioned before, there’s been several reports either showing changes in the tumor microenvironment, if you have fewer CD8 positive T-cells, more inhibitory markers within the microenvironment or within the T-cells before treatment. None of those are yet ready for prime time to be a biomarker quite yet, but I think we’ll learn more as we collect more data moving forward.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
